CAMBRIDGE, MA / ACCESS Newswire / September 2, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that five abstracts on its investigational mRNA therapeutics have been accepted for presentation at ...

Approved by French regulatory authorities, the trial positions STC-1010 as a potential first-line treatment option for patients with unresectable, locally advanced or metastatic colorectal cancer ...

NICE has approved enfortumab vedotin plus pembrolizumab as a first‑line treatment for advanced urothelial cancer, doubling progression‑free and overall survival and offering transformative benefit to ...

CRA career paths, Clinical Project Manager, Clinical Trial Manager, Medical Science Liaison, CRA progression, clinical research careers, career beyond CRA, PharmiWeb ...

Working with the Inno4Vac consortium coordinated by European Vaccine Initiative, Naobios will leverage Nuvonis’s Vero Cell Bank to support development of a controlled human infection model based on ...

LUND, SE / ACCESS Newswire / September 2, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and ...

The Global Bioinformatics Market is expected to grow at a rate of 13-14% by 2029. The rising government initiatives and funding for genomics research, increasing applications of bioinformatics in drug ...

The Patient Engagement Solutions Market is expected to witness a CAGR of 13-17 % in the forecast period, due to the increasing demand for patient-centered care and rapid technological advancements.

U.S. market entry set to begin for QIAstat-Dx Rise – a version of QIAstat-Dx for syndromic testing that combines unparalleled throughput with the easiest workflowQIAstat-Dx Rise launch can process up ...

The African Pharmaceutical Market is expected to witness 6-8% growth by 2029. An increasing population and urbanization, a growing prevalence of chronic diseases, and increasing healthcare spending ...

Roche and Alnylam are moving their RNAi hypertension therapy zilebesiran into a global Phase III cardiovascular outcomes trial after promising blood pressure reductions and safety signals in mid‑stage ...

VANCOUVER, BC / ACCESS Newswire / September 2, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:XPHYF)(FSE:4XT) is pleased to announce the receipt of the Semaglutide active ...